H3K27-altered diffuse midline glioma: a paradigm shifting opportunity in direct delivery of targeted therapeutics
Expert Opinion on Therapeutic Targets | February 6, 2023 | Volume: 27 | Issue: 1 | Pages: 9-17
10.1080/14728222.2023.2177531
| PMID 36744399